Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowe...(n Americans who suffer from D-IBS and A-...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Date:5/20/2008
n Americans who suffer from D-IBS and A-IBS.
About Asimadoline
Asimadoline is an orally administered small molecule that is a highly selective kappa opioid receptor agonist. Kappa opioid receptors are found in the digestive tract and are believed to play an important role in control of visceral pain and bowel motility. Asimadoline was originally discovered by Merck KGaA of Darmstadt, Germany. In 2005, Tioga purchased asimadoline from Merck and acquired by assignment all worldwide rights. Asimadoline has been tested in over 1100 subjects and has demonstrated a promising safety profile.
About Tioga
Tioga Pharmaceuticals, Inc. is a pharmaceutical company headquartered
in San Diego, CA focused on developing novel treatments for
gastrointestinal diseases. Tioga is currently planning Phase 3 development
of asimadoline for the treatment of D-IBS and A-IBS and a Phase 2b trial of
asimadoline for the treatment of functional dyspepsia. Both disorders
represent a large unmet medical need and a substantial market opportunity.
For more information, please visit http://www.tiogapharma.com.
Contact: David Urso, Chief Business Officer and General Counsel
Phone: 858-964-5021
Email: urso@tiogapharma.com
Media: Cory Tromblee, Porter Novelli Life Sciences
Phone: 617-897-8294
Email: ctromblee@pnlifesciences.com
'/>"/>
| SOURCE Tioga Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:11/25/2009)... According to Millennium Research ...ology market intelligence, the nearly $3 billion U... to see rapid growth over the next five years desp...s for Trauma Devices 2010 report finds that thi...five years, with competitors introducing specializ...
(Date:11/25/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Pain Management - Global Trends ,,...ment---Global-Trends.html ,, Widespread availa...ent clinics, and the advent of new drugs have acce...market. Healthcare reforms and reimbursement struc...
(Date:11/25/2009)...Y, Nov. 25 HeartWare Int...ding innovator and provider of less invasive, mini...onizing the treatment of advanced heart failure, t...estor presentation at the 21st Annual Piper Jaffra...ay, December 2, 2009. The conference is being held...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2iTech Medical Provides Update on MPR Clinical Development Plan 58632 1iTech Medical Provides Update on MPR Clinical Development Plan 58632 2iTech Medical Provides Update on MPR Clinical Development Plan 58632 3iTech Medical Provides Update on MPR Clinical Development Plan 58632 4Lumenis 28R 29 Introduces AcuPulse 28TM 29 for Fractional Laser Treatments 5131 1Lumenis 28R 29 Introduces AcuPulse 28TM 29 for Fractional Laser Treatments 5131 2Lumenis 28R 29 Introduces AcuPulse 28TM 29 for Fractional Laser Treatments 5131 3Lumenis 28R 29 Introduces AcuPulse 28TM 29 for Fractional Laser Treatments 5131 4Prix Galien USA Honors Innovation in Science and Biotech Industries 5128 1Prix Galien USA Honors Innovation in Science and Biotech Industries 5128 2..., Calif., June 04, 2007 /PRNewswire-FirstCall/ --,... positive Phase 2,results for the treatment of hot...d seventeen women were enrolled in the company,s,d... 2 trial.,Postmenopausal women with 50 or more mod...ed to one of three treatment groups receiving,MF10...
...pecified subset analyses of progression-free survi...trate a reduction in,relative risk of disease prog...analyses included prior Taxotere use,geographies,... June 04, 2007 /PRNewswire-FirstCall/ -- Pharmion,... presentation of,additional data from the double-b...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7(Date:11/27/2009)...swire/ - Uploadable USB pedometers may be new, but...combination of advanced accelerometer functionalit...m concern over the accuracy of self-reported data....improved participation in a fitness program. ,,...ess suppliers to integrate this technology. "Our h...
(Date:11/27/2009)...PRNewswire-USNewswire/ -- Preventing disease is th...ly every year, new vaccines are being added to ass...st immunity for the same period of time? And, if n...keep immunity strong? ,, In this month,s issu...my of Pediatrics, Michael Pichichero MD, Director ...
(Date:11/27/2009)...vehicles may reduce future disease burden, researc...News) -- Encouraging city dwellers to walk and bic...r public health benefits than increased used of lo..., The study compared the projected health effec...narios for London, England, and Delhi, India: bus...
(Date:11/27/2009)...e bilingual coloring books designed for children a...unity to educate - inform parents and children ali...Dinosuars to ABC,S and a host of other topics. , ...vember 27, 2009 -- Today’s children have eno... any hour of the day, but one of the oldest and si...
(Date:11/26/2009)... The diabetes population in the Un...ars and annual medical spending on the disease is ...n today, according to a study published in the Dec...nging Diabetes ® Program (NCDP), a program of... from the University of Chicago. ,, According t...
Breaking Medicine News(10 mins):Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4[0] New USB technology adds accountability and convenience to wellness programs[0] Why Some Vaccines May Require A Booster[0] More Foot Power, Less Car Pollution Best for Health[2] Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books [1] Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
... operations are set to take place in the UK as man...surgeons. Jacqueline Saburido who suffered 60% bur...do has already undergone several reconstruction su...About five patients will be identified by Butler, ...
...he scientific yet poetic explanation in the words ...t for men; but he who aspires to be a hero must dr...nce of brandy too. // Drinking 30ml of brandy has... University.
In the words of Gordon Troup fro...
...earing in the online journal Cancer says that elde...cer are more likely to develop full blown melanoma...of the sun. //
The study found that women in t...sk of developing cutaneous melanoma over 6.5 years...
...health agents have launched an inquiry into the or...se of the product has been stopped at the Californ... Advance // saliva test reportedly gives a result ...ated by officials belonging to the Centers for Dis...
...ospitals are flooded with patients with psychiatri...public hospitals has increased by 12% in the past ...d of psychiatric // health facilities.
Accordi...
But the pressure on the public hospitals is s...
...unteer of Médecins sans Frontières (MSF) in Kenya’...he area take their medication regularly, and also ...ef difficulty // for those who are afflicted with...to consume.
Volunteers help the nurses and ...
Other Medicine News:Health News:Community hospitals inundated with Psychiatric care cases (12%) 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |